This is an AMP page which is for mobile devices.

View Non AMP page

Twitter

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / MRK - Merck Phase 3 trial for Keytruda combo fails in lung cancer

MRK - Merck Phase 3 trial for Keytruda combo fails in lung cancer

March, 21 2024 07:22 AM Merck & Company Inc.

2024-03-21 07:22:10 ET

More on Merck

Merck & Co., Inc. (MRK) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
Merck & Co., Inc. (MRK) Management presents at Leerink Partners 2024 Global Biopharma Conference (Transcript)
Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference (Transcript)
Merck hits main goal for Keytruda in late-stage trial for cervical cancer
Merck to study single-dose regimen of HPV vaccine Gardasil 9

For further details see:

Merck Phase 3 trial for Keytruda combo fails in lung cancer

Stock Information

Company Name:	Merck & Company Inc.
Stock Symbol:	MRK
Market:	NYSE
Website:	merck.com

MRK MRK Quote MRK Short MRK News MRK Articles MRK Message Board

Get MRK Alerts

News, Short Squeeze, Breakout and More Instantly...

Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.